Among inflammatory bowel diseases (IBDs), every tenth develops during childhood, which is characterized by a more complex disease course, more extensive spread, and rapid progression. The presenting symptoms of pediatric-onset IBD are often nonspecific, and diagnostic delays increase the risk of intestinal damage, bowel resection, and growth retardation. Adolescents with IBD exhibit the lowest compliance and medication adherence rates, contributing to the frequent occurrence of complications. The most significant extraintestinal complications in pediatric-onset IBD patients include growth retardation, malnutrition, impaired bone metabolism, malignancies, and opportunistic infections. In this patient group, surgical interventions are required earlier and more frequently, and the hospitalization rate is also higher among them. Ensuring optimal disease progression and quality of life is crucial, making it essential for the physicians managing their care to be well aware of the specific characteristics of the pediatric-onset IBD patient group. Orv Hetil. 2025; 166(11): 403–412.
A gyulladásos bélbetegségek (IBD) 10–25%-a már gyermekkorban kialakul, melyekre jellemző a komplexebb betegséglefolyás, az extenzívebb kiterjedés és a gyors progresszió. A gyermekkori kezdetű IBD prezentációs tünetei gyakran aspecifikusak, a diagnosztikus késedelem hatására nő a bélkárosodás, a bélreszekció és a növekedésbeli elmaradás kockázata. A tinédzser IBD-s korosztály körében tapasztalható a legkisebb compliance és gyógyszeradherencia-ráta, ami hozzájárul a gyakori szövődmények megjelenéséhez. A legfontosabb extraintestinalis szövődmények a gyermekkori kezdetű IBD-s betegek körében a növekedésbeli elmaradás, a malnutritio, a csontanyagcsere-zavar, a malignitások és az opportunista fertőzések megjelenése. Ebben a betegcsoportban korábban és gyakrabban van szükség sebészeti beavatkozásokra, illetve körükben nagyobb a hospitalizációs arány is. Az optimális betegséglefolyás és életminőség biztosítása szempontjából kulcsfontosságú, hogy a gondozásukat végző orvosok tisztában legyenek a gyermekkori kezdetű IBD-s betegek sajátosságaival. Orv Hetil. 2025; 166(11): 403–412.
Matsui T, Yao T, Sakurai T, et al. Clinical features and pattern of indeterminate colitis: Crohn’s disease with ulcerative colitis-like clinical presentation. J Gastroenterol. 2003; 38: 647–655.
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417–429.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427–434.
Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630–649.
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014; 20: 91–99.
De Souza HS, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017; 14: 739– 749.
Hugot JP, Dumay A, Barreau F, et al. Crohn’s disease: is the cold chain hypothesis still hot? J Crohns Colitis 2021; 15: 678–686.
Cseh Á, Prehoda B, Tóbi L, et al. Up-to-date treatment of inflammatory bowel disease in childhood: focus on diet and biological therapy. [A gyulladásos bélbetegség korszerű kezelése gyermekkorban: fókuszban a diéta és a biológiai terápia.] Orv Hetil. 2023; 164: 963–970. [Hungarian]
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021; 18: 56–66.
Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011; 17: 423–439.
Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014; 147: 990–1007.e3.
Jakobsen C, Bartek J Jr, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease. A population-based study. Aliment Pharmacol Ther. 2011; 34: 1217–1224.
Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 839–849.
Benninga MA, Faure C, Hyman PE, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2016; 150: 1443–1455.
Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016; 10: 239–254.
Hyams JS, Di Lorenzo C, Saps M, et al. Functional disorders: children and adolescents. Gastroenterology 2016; 150: 1456–1468.e2.
Däbritz J, Gerner P, Enninger A, et al. Inflammatory bowel disease in childhood and adolescence. Dtsch Ärztebl Int. 2017; 114: 331–338.
Lovász BD, Kecse ÉK, Bak D, et al. Analysis of work productivity and quality of life in patients with inflammatory bowel disease. [A gyulladásos bélbetegségek társadalmi hatásai: a munkaképesség és az életminőség vizsgálata.] Orv Hetil. 2023; 164: 1974–1984. [Hungarian]
Tóbi L, Prehoda B, Balogh AM, et al. Transition is associated with lower disease activity, fewer relapses, better medication adherence, and lower lost-to-follow-up rate as opposed to self-transfer in pediatric-onset inflammatory bowel disease patients: results of a longitudinal, follow-up, controlled study. Therap Adv Gastroenterol. 2024; 17: .
Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114–1122.
Ballengee CR, Kugathasan S. Response to biologics delay progression of Crohn’s disease in children but not early surgery. Clin Gastroenterol Hepatol. 2018; 16: 1398–1400.
Atia O, Shosberger A, Focht G, et al. Development and validation of the IBD-REFER criteria: early referral for suspected inflammatory bowel diseases in adults and children. Crohns Colitis 360. 2020; 2: otaa027.
Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 63–68.
Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003; 88: 995–1000.
Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014; 11: 601–610.
Fumery M, Duricova D, Gower-Rousseau C, et al. Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies. Aliment. Pharmacol Ther. 2016; 43: 346–355.
Otto C, Tárnok A, Erős A, et al. Planned transition of adolescent patients with inflammatory bowel disease results in higher remission rates. J Pediatr Nurs. 2019; 45: 62–66.
Carroll MW, Kuenzig ME, Mack DR, et al. The impact of inflammatory bowel disease in Canada 2018: children and adolescents with IBD. J Can Assoc Gastroenterol. 2019; 2(Suppl 1): S49–S67.
Shuhart CR, Yeap SS, Anderson PA, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 2019; 22: 453–471.
Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009; 104: 2080–2088.
Benchimol EI, To T, Griffiths AM, et al. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system. J Pediatr. 2011; 158: 960–967.e1–e4.
Singh H, Nugent Z, Targownik LE, et al. Health care use by a population-based cohort of children with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015; 13: 1302–1309.e3.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.e42.
Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology 2008; 135: 1106–1113.
Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006; 12: 1093–1100.
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care – an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018; 67: 257–291. Erratum: J Pediatr Gastroenterol Nutr. 2020; 71: 794.
Moon JS. Clinical aspects and treatments for pediatric inflammatory bowel diseases. Pediatr Gastroenterol Hepatol Nutr. 2019; 22: 50–56.
Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 39–43.
Mackner LM, Crandall WV. Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 1006–1012.
Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008; 33: 867–874.
Olen O, Askling J, Sachs MC, et al. Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population. Gastroenterology 2019; 156: 614–622.